Status:
COMPLETED
Forxiga HF General Drug Use-Results Study
Lead Sponsor:
AstraZeneca
Conditions:
Heart Failure
Eligibility:
All Genders
15+ years
Brief Summary
To capture safety when Forxiga is administered to patients with HF in clinical practice after launch.
Detailed Description
The purpose of the study is to review the following points during use of Forxiga Tablets (hereinafter referred to as Forxiga) in the real world setting after launch. 1. ADRs which are unexpected from...
Eligibility Criteria
Inclusion
- Patients aged more than 15 years
- Patients who have been prescribed Forxiga for the first time
Exclusion
- Patients with a history of hypersensitivity to any ingredients of this drug.
- Patients with severe ketosis, diabetic coma or precoma
- Patients with severe infections, before or after a surgery, or with serious trauma
Key Trial Info
Start Date :
May 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 22 2024
Estimated Enrollment :
1221 Patients enrolled
Trial Details
Trial ID
NCT04865406
Start Date
May 10 2021
End Date
August 22 2024
Last Update
July 3 2025
Active Locations (45)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aichi, Japan
2
Research Site
Akita, Japan
3
Research Site
Aomori, Japan
4
Research Site
Chiba, Japan